Digirad releases second quarter, first half results

TriMed Staff | | Health Imaging | Screening
Digirad Corporation has announced financial results for the second quarter and first half of 2005. For the three months ended June 30, 2005, consolidated revenue declined 11 percent to $15.5 million from $17.3 million for the same period of 2004.

The net loss for the second quarter of 2005 was $3.0 million. This compares to net income for the second quarter of 2004 of $103,000.

For the six months ended June 30, 2005, total revenue was $33.4 million. This compares to total revenue of $33.2 million for first half 2004.

TriMed Staff

Related Content

AI reduces CT lung cancer screening workload by nearly 80%
Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans

Around the web

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Cardiovascular Business
Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.